Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a Study of JNJ-40346527 in Active Rheumatoid Arthritis Despite DMARD Therapy
2011-004529-28Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing JNJ-40346527 200 mg/day with Placebo (2 arms). Primary endpoint: Change from baseline in DAS28-CRP at Week 12. Started Mar 2012; status: completed.
02
Drugs
edicotinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2011-004529-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004529-28.